Targeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed Drugs

用新用途药物靶向治疗肺动脉高压的新型 BMPR2 修饰剂

基本信息

  • 批准号:
    9923720
  • 负责人:
  • 金额:
    $ 43.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-05-01 至 2021-04-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant: There is a fundamental gap between our current treatment for Pulmonary Arterial Hypertension (PAH) with primarily vasodilators, and the need to reverse the occlusive vasculopathy of pulmonary arteries that results in increased pulmonary vascular resistance and right heart failure. Increasingly, Bone Morphogenetic Protein Receptor 2 (BMPR2) signaling is recognized as a key pathway and potential master switch in PAH with reduced BMPR2 expression implicated in vascular cell proliferation and occlusive vasculopathy. The overall goal of this proposal thus is to develop new therapies to reverse the occlusive vasculopathy by novel pathways that increase BMPR2 expression. The mechanism by which BMPR2 is downregulated in PAH patients is not known. Strategies to increase BMPR2 signaling have shown promise in experimental pulmonary hypertension yet most approaches still face many obstacles before they can be used clinically. Thus, identifying BMPR2 modifier genes that could be harnessed with repurposed drugs to increase BMPR2 expression would be a promising strategy to improve PAH with a clear path to therapeutic translation. Our proposal has three significant parts, which are represented by our three specific aims: First, we will focus on novel BMPR2 modifier genes, Fragile Histidine Triad (FHIT) and Lymphocyte specific protein tyrosine Kinase (LCK) that we identified in an siRNA High Throughput Screen (HTS) and that are not only functionally important in PAH but also highly represented in a meta-analysis of PAH transcriptomic databases. Our strong preliminary data showed that decreased expression of FHIT and LCK resulted in reduced BMPR2 mRNA expression and impaired function of pulmonary vascular cells. Our studies on human PAH lung tissue, endothelial as well as immune cells suggested that FHIT and LCK are downregulated in PAH and modify disease penetrance in familial PAH. Second, we will determine how FHIT and LCK regulate BMPR2 on the epigenetic and transcriptional level using candidate and unbiased profiling assay approaches. Third, we will determine whether a drug that increases FHIT, Enzastaurin, reverses the abnormal phenotype of human vascular cells and experimental pulmonary hypertension, thus offering a clear path to a therapeutic translation. Three innovative aspects underlie our approach: (1) conceptually, we will target BMPR2 expression by modulating two novel genes that have not been describe in PAH before (2) technically, we used a novel siRNA high Throughput Screen that has not been used to identify BMPR2 modifier genes in PAH and (3) pharmacologically, we will repurpose existing drugs which not only saves time and expense but can speed their adoption in the clinic because of known safety and toxicity information from regulatory agencies. The contribution of our proposed research is highly significant to the field o PAH, as it utilizes novel pathways to regulate BMPR2 gene expression by repurposing drugs not previously linked to either the receptor or to PAH.
 描述(由申请人提供):我们目前主要使用血管扩张剂治疗肺动脉高压(PAH)与需要逆转导致肺血管阻力增加和右心衰竭的肺动脉闭塞性血管病变之间存在根本性差距。骨形态发生蛋白受体2(BMPR 2)信号传导越来越多地被认为是PAH的关键途径和潜在的主开关,BMPR 2表达减少与血管细胞增殖和闭塞性血管病变有关。因此,该提案的总体目标是开发新的疗法,以通过增加BMPR 2表达的新途径来逆转闭塞性血管病变。PAH患者中BMPR 2下调的机制尚不清楚。增加BMPR 2信号转导的策略在实验性肺动脉高压中显示出希望,但大多数方法在临床应用之前仍然面临许多障碍。因此,鉴定可以与再利用药物一起利用以增加BMPR 2表达的BMPR 2修饰基因将是改善PAH的有希望的策略,具有明确的治疗转化途径。我们的建议有三个重要的部分,这是由我们的三个具体目标所代表的:首先,我们将专注于新的BMPR 2修饰基因,脆性组氨酸三联体(FHIT)和淋巴细胞特异性蛋白酪氨酸激酶(LCK),我们在siRNA高表达筛选(HTS)中鉴定,不仅在PAH中功能重要,而且在PAH转录组数据库的荟萃分析中高度代表。我们的初步研究结果表明,FHIT和LCK的表达减少导致BMPR 2 mRNA表达减少,肺血管细胞功能受损。我们对肺动脉高压患者肺组织、内皮细胞和免疫细胞的研究表明,FHIT和LCK在肺动脉高压中表达下调,并改变家族性肺动脉高压的疾病发生率。其次,我们将确定如何FHIT和LCK调节BMPR 2的表观遗传和转录水平上使用候选人和无偏的分析方法。第三,我们将确定一种增加FHIT的药物,Enzaelectin,是否逆转人类血管细胞和实验性肺动脉高压的异常表型,从而为治疗转化提供一条明确的道路。我们的方法有三个创新方面:(1)概念上,我们将通过调节两种以前在PAH中未描述过的新基因来靶向BMPR 2表达;(2)技术上,我们使用了一种新的siRNA高表达筛选,该筛选尚未用于鉴定PAH中的BMPR 2修饰基因;和(3)靶向,我们将重新利用现有的药物,这不仅节省时间和费用,而且可以加快临床采用这些药物,因为监管机构提供了已知的安全和毒性信息。我们提出的研究对PAH领域的贡献非常重要,因为它利用新的途径通过重新利用以前未与受体或PAH相关的药物来调节BMPR 2基因表达。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Edda Frauke Spiekerkoetter其他文献

Edda Frauke Spiekerkoetter的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Edda Frauke Spiekerkoetter', 18)}}的其他基金

Understanding and targeting molecular and cellular events responsible for pulmonary arteriovenous malformation development, growth and regression
了解和靶向导致肺动静脉畸形发生、生长和消退的分子和细胞事件
  • 批准号:
    10718086
  • 财政年份:
    2023
  • 资助金额:
    $ 43.65万
  • 项目类别:
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs
使用重新利用的药物了解和靶向控制肺动脉高压右心室适应、衰竭和恢复的分子和结构事件
  • 批准号:
    10615148
  • 财政年份:
    2021
  • 资助金额:
    $ 43.65万
  • 项目类别:
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs
使用重新利用的药物了解和靶向控制肺动脉高压右心室适应、衰竭和恢复的分子和结构事件
  • 批准号:
    10456651
  • 财政年份:
    2021
  • 资助金额:
    $ 43.65万
  • 项目类别:
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs
使用重新利用的药物了解和靶向控制肺动脉高压右心室适应、衰竭和恢复的分子和结构事件
  • 批准号:
    10278668
  • 财政年份:
    2021
  • 资助金额:
    $ 43.65万
  • 项目类别:
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
调节肺动脉高压中的 BMPRII 信号传导
  • 批准号:
    8890864
  • 财政年份:
    2011
  • 资助金额:
    $ 43.65万
  • 项目类别:
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
调节肺动脉高压中的 BMPRII 信号传导
  • 批准号:
    8308378
  • 财政年份:
    2011
  • 资助金额:
    $ 43.65万
  • 项目类别:
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
调节肺动脉高压中的 BMPRII 信号传导
  • 批准号:
    8520385
  • 财政年份:
    2011
  • 资助金额:
    $ 43.65万
  • 项目类别:
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
调节肺动脉高压中的 BMPRII 信号传导
  • 批准号:
    8703752
  • 财政年份:
    2011
  • 资助金额:
    $ 43.65万
  • 项目类别:
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension
调节肺动脉高压中的 BMPRII 信号传导
  • 批准号:
    8091016
  • 财政年份:
    2011
  • 资助金额:
    $ 43.65万
  • 项目类别:

相似海外基金

WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 43.65万
  • 项目类别:
    Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 43.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 43.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 43.65万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 43.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 43.65万
  • 项目类别:
    EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 43.65万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 43.65万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 43.65万
  • 项目类别:
    Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 43.65万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了